Tempero Bio

Focus: Tempero Bio is a pre-revenue biotech company focused on developing treatments for substance use disorders, currently operating at a very early stage with a micro-scale team of 1-50 employees.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

1-50

Open Jobs

About Tempero Bio

AI assessmentNot Hiring

No open roles listed right now. Follow Tempero Bio to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Cohort 1 - TMP-301

Cocaine Use Disorder

PHASE_1

Clinical Trials (1)

NCT06025396Multiple Ascending Dose Study of TMP-301 in Healthy Subjects

Phase 1

Help build intelligence for Tempero Bio

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work on an underserved therapeutic area (substance use disorders) with significant unmet medical need and potential for outsized social impact
Early-stage exposure means broad responsibility and direct influence on compound development strategy and data generation
Lead candidate TMP-301 advancing into Phase 2 for alcohol use disorder, de-risking the platform

Watch Out For

Pre-revenue, public-stage company with no disclosed funding, raising material uncertainty about runway and financial stability
Zero active job openings and micro-scale team (1-50 employees) suggests limited hiring velocity and career growth pathways
Very early pipeline (Phase 1-2 only) with no Phase 3 programs means 5+ years minimum to potential approval and revenue inflection

Generated by Claude from Tempero Bio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

TMP-301

Cocaine Use Disorder

PHASE_1

Clinical Trials (1)

NCT06648668A Study to Investigate the Interaction Between TMP-301 and Cocaine.

Phase 1

TMP-301

Alcohol Use Disorder (AUD)

PHASE_2

Clinical Trials (1)

NCT06648655A Study to Investigate the Safety and Efficacy of TMP-301 Compared to Placebo in Adult Patients With Alcohol Use Disorder

Phase 2